Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eye Functioning in Adults With ADHD Treated With Methylphenidate, Melatonin, or Light Therapy
NL-OMON22441Phase 3Recruiting
- Sponsor
- PsyQ
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylphenidate and melatonin in attention deficit hyperactivity disorder (ADHD) (6 arms), sponsored by PsyQ. Primary endpoint: Change in post-illumination pupil response. Started Feb 2015; status: recruiting.
02
Drugs
methylphenidatemelatonin
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON22441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22441.